{"id":"frsw117","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, FRSW117 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. Its exact mechanism of action is still being studied in clinical trials.","oneSentence":"FRSW117 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:26.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06142552","phase":"PHASE3","title":"Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein","status":"RECRUITING","sponsor":"Jiangsu Gensciences lnc.","startDate":"2023-12-27","conditions":"Severe Hemophilia A","enrollment":120},{"nctId":"NCT04864743","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection","status":"COMPLETED","sponsor":"Jiangsu Gensciences lnc.","startDate":"2021-06-22","conditions":"Severe Hemophilia A","enrollment":13},{"nctId":"NCT05265286","phase":"PHASE2","title":"A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection","status":"COMPLETED","sponsor":"Jiangsu Gensciences lnc.","startDate":"2022-04-14","conditions":"Severe Hemophilia A","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection","Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection"],"phase":"phase_3","status":"active","brandName":"FRSW117","genericName":"FRSW117","companyName":"Jiangsu Gensciences lnc.","companyId":"jiangsu-gensciences-lnc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FRSW117 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}